XNAS
ATNF
Market cap5mUSD
Jun 10, Last price
1.04USD
1D
-1.88%
1Q
-11.11%
IPO
-99.97%
Name
180 Life Sciences Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
99.40%
Rev. gr., 5y
%
Revenues
0k
Net income
-6m
L-69.06%
CFO
-1m
L-86.44%
Earnings
Aug 11, 2025
Profile
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 5,757 | 13,583 | 18,007 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (5,757) | (13,583) | (18,007) | |||||
NOPBT Margin | ||||||||
Operating Taxes | (296) | (2,349) | 943 | |||||
Tax Rate | ||||||||
NOPAT | (5,461) | (11,234) | (18,950) | |||||
Net income | (6,168) -69.06% | (19,935) -48.52% | (38,726) 90.54% | |||||
Dividends | (8,012) | |||||||
Dividend yield | 480.89% | |||||||
Proceeds from repurchase of equity | 2,573 | 5,999 | 11,485 | |||||
BB yield | -154.43% | -390.14% | -178.27% | |||||
| Debt | ||||||||
Debt current | 148 | 1,034 | 1,309 | |||||
Long-term debt | 20 | 31 | ||||||
Deferred revenue | (31,189,000) | |||||||
Other long-term liabilities | 7 | 31,189,000 | ||||||
Net debt | (4,437) | (922) | (5,630) | |||||
| Cash flow | ||||||||
Cash from operating activities | (1,481) | (10,922) | (12,128) | |||||
CAPEX | 3 | |||||||
Cash from investing activities | ||||||||
Cash from financing activities | 4,038 | 5,908 | 10,874 | |||||
FCF | (5,849) | (10,845) | (25,539) | |||||
| Balance | ||||||||
Cash | 4,585 | 1,976 | 6,970 | |||||
Long term investments | ||||||||
Excess cash | 4,585 | 1,976 | 6,970 | |||||
Stockholders' equity | (144,440) | (130,245) | (110,294) | |||||
Invested Capital | 153,846 | 131,171 | 122,977 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 915 | 379 | 100 | |||||
Price | 1.82 -55.13% | 4.06 -93.70% | 64.41 -95.65% | |||||
Market cap | 1,666 8.34% | 1,538 -76.13% | 6,442 -94.73% | |||||
EV | (2,771) | 616 | 812 | |||||
EBITDA | (5,449) | (13,478) | (17,898) | |||||
EV/EBITDA | 0.51 | |||||||
Interest | 51 | 27 | ||||||
Interest/NOPBT | ||||||||